Pediatric Extensions: The Six-Month Premium The BPCA and PREA Incentive Structure The Best Pharmaceuticals for Children Act (BPCA), first enacted in 1997 and renewed multiple times since, grants a six-month extension of all existing exclusivity, including any PTE, to companies that conduct FDA-requested pediatric studies on their drug
The choice between these medications requires a thoughtful evaluation of individual needs, priorities, and treatment goals, underscoring the importance of personalized medicine in navigating the landscape of GLP-1 receptor agonists
They enhance glucose-dependent insulin secretion from pancreatic beta cells, meaning insulin is released primarily when blood glucose levels are elevated, which reduces the risk of hypoglycemia compared to some other diabetes medications
Different subtypes involve different dominant mechanisms, and peptide selection should reflect these differences
Joh Science Advances .2025;[Epub] CrossRef Shallow whole-genome sequencing of circulating tumour DNA predicts clinical outcomes to systemic therapy in advanced hepatocellular carcinoma Venkata Ramana Mallela, Sultan N